| Literature DB >> 35886869 |
Valentina Anuța1, Marina-Theodora Talianu1, Cristina-Elena Dinu-Pîrvu1, Mihaela Violeta Ghica1, Răzvan Mihai Prisada1, Mădălina Georgiana Albu Kaya2, Lăcrămioara Popa1.
Abstract
Oral candidiasis has a high rate of development, especially in immunocompromised patients. Immunosuppressive and cytotoxic therapies in hospitalized HIV and cancer patients are known to induce the poor management of adverse reactions, where local and systemic candidiasis become highly resistant to conventional antifungal therapy. The development of oral candidiasis is triggered by several mechanisms that determine oral epithelium imbalances, resulting in poor local defense and a delayed immune system response. As a result, pathogenic fungi colonies disseminate and form resistant biofilms, promoting serious challenges in initiating a proper therapeutic protocol. Hence, this study of the literature aimed to discuss possibilities and new trends through antifungal therapy for buccal drug administration. A large number of studies explored the antifungal activity of new agents or synergic components that may enhance the effect of classic drugs. It was of significant interest to find connections between smart biomaterials and their activity, to find molecular responses and mechanisms that can conquer the multidrug resistance of fungi strains, and to transpose them into a molecular map. Overall, attention is focused on the nanocolloids domain, nanoparticles, nanocomposite synthesis, and the design of polymeric platforms to satisfy sustained antifungal activity and high biocompatibility with the oral mucosa.Entities:
Keywords: antifungal mechanisms; cellular response; epithelial damage; graphene oxide; inorganic materials; nanocolloids; nanotechnological features; oral candidiasis; polymers; vegetable resources
Mesh:
Substances:
Year: 2022 PMID: 35886869 PMCID: PMC9320712 DOI: 10.3390/ijms23147520
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Local and systemic triggers defined by surface and molecular changes, involved in candidiasis development and pathogenesis.
| Local Factors | ||
|---|---|---|
| Factors | Surface and Molecular Effects | Ref. |
| Imbalances in salivary flow | A high number of | [ |
| Dentures | Dentures decrease O2 supply at the epithelial level and reduce the salivary flow, creating a favorable acidic medium for yeast development. The fungi have an increased affinity for the roughened hydrophobic surfaces of acrylic resins of dentures, encouraging biofilm generation and the initiation of stomatitis. The adhesion process is promoted by a gradual replacement of interfacial water. Intimate mechanisms involved in biofilm formation are the roughness of the surface, hydrophobicity, and electrostatic nature of interactions prior to promoting protein adsorption and adhesion, Lifshitz–van der Waals forces, Brownian motion, and receptor–ligand binding. | [ |
| Prosthesis | Dental implants favor the localization of | [ |
| Pre-existing oral | Denture stomatitis is promoted by modification in E-cadherin, collagen VII and fibronectin, combined with the presence of | [ |
| Poor epithelial | Reduced response of the host immune defense elements (Toll-like receptors, C-type lectin receptors, and 2 NOD-like receptors) induces dissemination of virulence factors, specific for | [ |
| Oral dysbiosis | The oral microbiome covers a large number of microorganisms, up to 700 species, of which more than 60 are fungi species. A reduction in the number of native fungi that normally harbor the buccal mucosa was associated with the risk of developing oral infections. The interactions between fungal entities and bacteria such as streptococci favor the development of mixed biofilms and modulate the mechanisms implied in polymorphism and host immune response. The interactions of streptococci with | [ |
| Inhalator corticosteroids | The treatment with inhalator corticosteroids causes a poor epithelial local defense of the immune system and was thought to elevate salivary glucose levels as a substrate for fungi growth. Oral candidiasis development was dependent on dose and the device used in administration. | [ |
| Smoking | Several theories consider the epithelial damage induced by smoking. In a more profound understanding, a concentration of 1–2 mg/mL of nicotine was found to assure the process of fungi cell multiplication, and it was correlated with an increase in HWP1 and ALS3 expression, implied in hyphae expansion and biofilm formation. | [ |
| Carbohydrate-based diet | The intake of dietary and sugar-based foods represents a substrate for candidiasis development. High glucose levels in diabetic patients influence oral candidiasis development as well. | [ |
|
| ||
|
|
|
|
| Vitamin and mineral | Candidiasis development can be promoted by vitamin A, B6, and B12 deficiency, iron deficiency, or a reduced level of essential fatty acids, folic acid, magnesium, selenium, or zinc. | [ |
| Metabolic disorders | Diabetic patients are highly predisposed to oral candidiasis, which can be seen as a pathological result of an accumulation of factors: poor oral hygiene, xerostomia, pH imbalances, increase in serum glucose levels, and poor epithelial local defense alike. | [ |
| Menopause | A decrease in estrogen hormone levels in menopausal women can counteract the normal state of the oral mucosa. A hormonal change can induce a cascade of local effects involving the modification in salivary secretion, lysozyme decrease, poor local immune activity, and an increase in oxidative stress. | [ |
| HIV immunodeficiency | Immunosuppression that can be quantified by a decreased number of CD4+ immune cells entails an increased risk of developing candidiasis. A decrease in histatins level contributes to the severity of the pathology. | [ |
| Prolonged antibiotherapy | Administration of broad-spectrum antibiotics yields dysbiosis, affecting the normal oral flora and transforming the commensal microorganisms into pathogenic entities. Imbalances in oral microbiota were related to a decrease in salivary antibody content. Salivary proteins expressed as mucins, salivary IgA, cystatin S, basic proline-rich proteins, or statherins are implied in a dynamic process concerning adhesion/aggregation/clearance of fungal cells. | [ |
| Immunosuppressive | Immunosuppressive and cytotoxic treatments of malignancies promote a weakening of the immune system, with repercussions for epithelial cell defense. Resistance to antifungal therapy was observed due to the formation of biofilms with persistent | [ |
| COVID-19 | COVID-19 induces immunosuppression by decreasing CD4+ and CD8+ T immune cells. In addition, candidiasis development in its invasive form has a multifactorial pattern, drawn by the presence of comorbidities (diabetes mellitus, pulmonary disorders, and malignancies) and concomitant treatments with immunosuppressants, corticosteroids, or antibiotics. Once more, a decrease in the salivary level of AMP was considered to be a robust marker for both superficial and intrusive infections. | [ |
Note: 1 ErbB1 (Her1) represents eukaryotic ribosome biogenesis protein, 2 NOD-like receptors—nucleotide-binding and oligomerization domain receptors, 3 ALS1—agglutinin-like sequence-1, 4 ALS3—agglutinin-like sequence-3, 5 HWP1—hyphae wall protein-1, 6 cAMP/PKA represents the cyclic adenosine monophosphate/protein kinase A pathway, and 7 MAP kinase—mitogen-activated protein kinase.
Figure 1Dynamics in the colonization process of the oral mucosa with C. albicans and molecular processes, triggering yeast to hyphae transition and invasion.
Figure 2Cell wall structure and host immune defense in C. albicans epithelial infection.
Classic antifungal drugs, their mechanisms of action, and major drawbacks in terms of fungal resistance to antifungal therapy.
| Therapeutic Class | Antifungal Drugs— | Mechanisms of Action | Mechanisms of Resistance | Drug-Related | Ref. |
|---|---|---|---|---|---|
| Polyenes | Nystatin | Target the ergosterol sites and disrupt the cellular membrane, promoting fungicidal effects. | Modification of enzymes with catalytic activity (C8-sterol isomerase and Δ5,6-desaturase), implied in ergosterol biosynthesis, via ERG2 and ERG3 gene alteration. | Nystatin is used only for its local effect, without systemic absorption. It has an unpleasant taste in buccal administration. | [ |
| Amphotericin B is nephrotoxic and preferred as second-line therapy. | |||||
| Poor bioavailability. | |||||
| Azoles | Clotrimazole | Inhibition of cytochrome P450 enzymes implied in the biosynthesis of ergosterol from lanosterol, namely 14-α demethylase. | Overexpression of CDR1 and CDR2 of the ATP-binding cassette superfamily, and MDR1 (major facilitator superfamily) genes. | Poor bioavailability, and buccal delivery of azoles is less efficient (multiple dosings and short local retention). | [ |
| Echinocandins | Micafungin | Fungicidal effects induced via inhibition of β (1–3) glucan synthase. Drug molecules target cell wall proteins implied in β (1–3) glucan synthesis. | Mutation of FKS1 gene specific for the catalytic unit of glucan synthase. | Poor bioavailability, and the intravenous route (i.v.) is only accepted for systemic treatment. | [ |
| Pyrimidines | 5-fluorocytosine | Cytosine permease entraps drug molecules into the cells. 5-fluorocytosine is bio transformed in 5-fluorouracil in the presence of cytosine deaminase. The new compound alters RNA synthesis and consequently protein synthesis. A second conversion through fluoro-deoxyuridylic acid determines DNA alteration. | Mutations in cytosine permease and cytosine deaminase enzymes. | Drug monitoring is mandatory for oral and i.v. route to avoid immunosuppression and hepatotoxicity. | [ |
Figure 3Microemulsion mechanism at the contact with the fungi cell wall and implications in drug processing and delivery.
Figure 4Antifungal activity and molecular effects of silver and copper oxide inorganic nanoparticles in C. albicans strains.
Figure 5Antifungal activity and molecular effects of graphene oxide biomaterials in C. albicans strains.
Figure 6Antifungal activity support and molecular effects of polymer-based biomaterials.